Loading...
Home2019-02-22T21:28:21+00:00

Unprecedented Insights

ImaginAb is an emerging immune-oncology imaging company developing a pipeline of novel products that give physicians unprecedented insights into the patient’s health—enabling better patient selection and treatment monitoring for immuno-oncology therapies and other drugs.

Harnessing the specificity of monoclonal antibodies, ImaginAb designs and engineers small, highly targeted proteins known as minibodies that image important molecular targets using standard Positron Emission Tomography (PET).

Our imaging tools help physicians answer important clinical questions, improving the path of care and ultimately helping patients live longer, healthier lives.

We image critical targets in immuno-oncology to help patients and their doctors make better-informed treatment decisions.

Our approach
100%

ACCURACY

100%

INNOVATION

100%

CLARITY

100%

BETTER DATA

Read latest publications

ImaginAb Announces change in management and strengthening of the Board of Directors and the Scientific Advisory Board

ImaginAb, Inc., a clinical stage immuno-oncology imaging company, announced today the appointment of Ian Wilson as Chief Executive Officer while Martyn Coombs steps down for family reasons, effective immediately. In addition, Tim Irish has joined ImaginAb’s Board of Directors as an independent non-executive Director and Jeffrey Evelhoch, Ph.D. has joined the Company’s Scientific Advisory Board.

ImaginAb Enrolls First Patient in Phase II Clinical Trial

ImaginAb Inc., an emerging immuno-oncology imaging company, announced today the enrollment of the first patient in the Phase II clinical trial of ImaginAb’s CD8+ T Cell imaging agent. The trial will enroll metastatic cancer patients and will study the correlation of imaging signals observed using ImaginAb’s CD8+ T cell ImmunoPET imaging agent, standard-of-care scans, and immunohistochemistry analysis of CD8 in biopsied tissues.

ImaginAb Announces Immuno-Oncology License and Clinical Trial Collaboration with Nektar Therapeutics

ImaginAb Inc., an immuno-oncology imaging company, today announced that it has entered into a non-exclusive license and clinical trial collaboration with Nektar Therapeutics (Nasdaq: NKTR). Under the terms of the agreement, Nektar will use ImaginAb’s CD8 ImmunoPET technology to measure whole body and tumor CD8+ T cells’ density and distribution in cancer patients.